Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by standudu
Group name EquipeCTCS
Item Type Journal Article
Title Evolution of overall survival and receipt of new therapies by subtype among 20?446 metastatic breast cancer patients in the 2008-2017 ESME cohort
Creator Grinda et al.
Author T. Grinda
Author A. Antoine
Author W. Jacot
Author C. Blaye
Author P.-H. Cottu
Author F. Dalenc
Author M. Debled
Author A. Patsouris
Author M.-A. Mouret-Reynier
Author A. Mailliez
Author F. Clatot
Author C. Levy
Author J.-M. Ferrero
Author I. Desmoulins
Author L. Uwer
Author T. Petit
Author C. Jouannaud
Author M. Lacroix-Triki
Author E. Deluche
Author M. Robain
Author C. Courtinard
Author T. Bachelot
Author E. Brain
Author D. Pérol
Author S. Delaloge
Abstract BACKGROUND: Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients who initiated their treatment in 18 French Cancer Centres since 2008. PATIENTS AND METHODS: We evaluated overall survival (OS) in the whole cohort (N = 20?446) and among subtypes: hormone receptor positive, human epidermal growth factor 2 negative (HR+/HER2-; N = 13 590), HER2+ (N = 3919), and triple-negative breast cancer (TNBC; N = 2937). We performed multivariable analyses including year of MBC diagnosis as one of the covariates, to assess the potential OS improvement over time, and we described exposure to newly released drugs at any time during MBC history by year of diagnosis (YOD). RESULTS: The median follow-up of the whole cohort was 65.5 months (95% CI 64.6-66.7). Year of metastatic diagnosis appears as a strong independent prognostic factor for OS [Year 2016 HR 0.89 (95% CI 0.82-0.97); P = 0.009, using 2008 as reference]. This effect is driven by the HER2+ subcohort, where it is dramatic [Year 2016 HR 0.52 (95% CI 0.42-0.66); P < 0.001, using 2008 as reference]. YOD had, however, no sustained impact on OS among patients with TNBC [Year 2016 HR 0.93 (95% CI 0.77-1.11); P = 0.41, using 2008 as reference] nor among those with HR+/HER2- MBC [Year 2016 HR 1.02 (95% CI 0.91-1.13); P = 0.41, using 2008 as reference]. While exposure to newly released anti-HER2 therapies appeared very high (e.g. >70% of patients received pertuzumab from 2016 onwards), use of everolimus or eribulin was recorded in less than one-third of HR+/HER2- and TNBC cohorts, respectively, whatever YOD. CONCLUSION: OS has dramatically improved among HER2+ MBC patients, probably in association with the release of several major HER2-directed therapies, whose penetrance was high. This trend was not observed in the other subtypes, but the impact of CDK4/6 inhibitors cannot yet be assessed.
Publication ESMO open
Volume 6
Issue 3
Pages 100114
Date 2021-06
Journal Abbr ESMO Open
Language eng
DOI 10.1016/j.esmoop.2021.100114
ISSN 2059-7029
Library Catalog PubMed
Extra PMID: 33895695 PMCID: PMC8095121
Tags Cohort Studies, Epidermal Growth Factor, HER2, Humans, marque, metastatic breast cancer, new drugs, original, overall survival, real-life, Receptor, ErbB-2, Retrospective Studies, Triple Negative Breast Neoplasms
Date Added 2022/07/29 - 15:52:26
Date Modified 2022/08/01 - 13:30:47
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés